Saffron activist held for derogatory FB post against UT Khader

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Bengaluru, Jan 23: Expressing shock over the blast which left him and his supporters injured yesterday, Shantinagar MLA NA Haris today said that the incident cannot be brushed aside as a firecracker blast and appealed to the state government to inquire into the incident.

Recovering from the injuries sustained on his leg, Haris was discharged from St Philomena's Hospital on Thursday afternoon. 

Interacting with mediapersons outside his residence in Shantinagar, Haris said, “It wasn’t a cracker but a ball-like object that was hurled at me. Since my childhood, I have been seeing crackers and the object that was thrown at me was certainly not a cracker. It had splinters and hard objects.”

He said, “I have been representing the constituency for over 12-years and had no rivalry with anyone. Barring political ideology during elections, all the leaders in our constituency have been cooperative with each other. Yet, we do not know what the intention was or who was behind the incident.”

Revealing that home minister Basavaraj Bommai had called him to enquire about his condition at the hospital Haris said, “I have also briefed the home minister and explained to him what exactly happened. I have full faith in the police and will cooperate with the police during the investigation.” Haris said that doctors have advised him three to four-days of rest.

Bengaluru, Mar 3: Karnataka Health Minister B Sriramulu has said that a medical team is monitoring the health condition of all those people who had stayed with the coronavirus-hit techie who is admitted to a hospital in Hyderabad.

The first confirmed case of the novel coronavirus (COVID-19) in Telangana was reported from Hyderabad on Monday where a man from Bengaluru, who recently returned from Dubai, tested positive for the virus.

"It has come to our knowledge that the coronavirus-hit person in Hyderabad had gone from Bengaluru. Therefore, all the members in the house where he had stayed here have been identified and are under watch," Mr Sriramulu tweeted on late Monday night.

The minister said he has convened a meeting with the additional chief secretary, commissioner and other senior officials of the health department today.

"Our government has initiated all the measures to prevent the spread of this virus," the minister said.

It is learnt that the 24-year-old techie had not contracted it when he was in Bengaluru but all precautionary measures have been taken.

The software engineer, who works in Bengaluru, had worked with people from Hong Kong in Dubai last month where he is suspected to have contracted the virus, Telangana health minister E Rajender told reporters in Hyderabad.

The man reached Bengaluru on February 19/20 and later went to Hyderabad in a bus.

He took treatment for fever after coming to Hyderabad and was admitted to a private super speciality hospital in the city. As it did not subside, he came to the state-run Gandhi hospital on Sunday evening, Mr Rajender said.